Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.30 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.30 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.30 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.30 |
| ▸ | GPR3 | P46089 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6855382 | 0.99 | SMN1; SMN2 (0.32) | SMN1; SMN2MAPTTSHRABCC9ABCC8 | |
| SCHEMBL5849584 | 0.88 | HTR6 (0.33) | ABCC9ABCC8KCNJ11KCNJ8CA1 | |
| Trifluoromethanesulfonic Acid SCHEMBL6855511 | 0.87 | GPR3 (0.39) | SMN1; SMN2MAPTTSHRGPR3 | |
| SCHEMBL3132979 | 0.83 | CA1 (0.35) | SMN1; SMN2GPR3CA1CA2 | |
| SCHEMBL546898 | 0.83 | CA1 (0.35) | SMN1; SMN2GPR3CA1CA2 | |
| SCHEMBL3132822 | 0.83 | CA1 (0.35) | SMN1; SMN2GPR3CA1CA2 | |
| SCHEMBL1089841 | 0.83 | CA1 (0.35) | SMN1; SMN2GPR3CA1CA2 | |
| SCHEMBL562807 | 0.83 | CA2 (0.36) | CA1CA2 | |
| SCHEMBL2898530 | 0.82 | ACHE (0.39) | MAPT | |
| SCHEMBL3129912 | 0.81 | GPR3 (0.35) | SMN1; SMN2GPR3CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6830868-B2 | Useful as a chemically amplified resist responding to active radiation, for example ultraviolet rays such as a KrF excimer laser, ArF excimer laser, and F2 excimer laser | JSR CORPORATION (JP) | 2004-12-14 | — | — | US | disclosed |
| US-20030194634-A1 | Novel anthracene derivative and radiation-sensitive resin composition | JSR CORPORATION (JP) | 2003-10-16 | — | — | US | disclosed |
| EP-1343048-A2 | Anthracene derivative and radiation-sensitive resin composition | JSR Corporation (JP) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030194634-A1 | Novel anthracene derivative and radiation-sensitive resin composition | SRSF1, ARL1, ERCC4 | SMN1; SMN2 2465/4885MAPT 3692/4885TSHR 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.